Clinical Trials Logo

Pancreas Adenocarcinoma clinical trials

View clinical trials related to Pancreas Adenocarcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06464965 Not yet recruiting - Gastric Cancer Clinical Trials

Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer

Start date: June 13, 2024
Phase: Phase 1
Study type: Interventional

Main Objective: To study the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 in patients with advanced gastric cancer and advanced pancreatic cancer. Secondary Objective: To evaluate the efficacy of CB CAR-NK182 in patients with advanced gastric cancer and advanced pancreatic cancer: overall objective tumor response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), etc. To evaluate the CAR-NK amplification and persistence of CB CAR-NK182 in the blood of patients with advanced gastric cancer and advanced pancreatic cancer;

NCT ID: NCT06381882 Not yet recruiting - Pancreas Cancer Clinical Trials

The Role of the Human Microbiome in Patients After Pancreatic Resection.

MiPac
Start date: May 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to classify patients that undergo pancreatic resection for presumed pancreatic or periampullary malignancy into high and low risk groups for postoperative complications based on longitudinal saliva, rectal/faecal, tumor, blood and/or bile microbiome profiles. To identify the dynamics of the microbiome, as well as the possibly related short-term and long-term complications, multiple samples at different timepoints are needed from the patients.

NCT ID: NCT06110598 Not yet recruiting - Pancreas Cancer Clinical Trials

CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

- This study is being done to find out if extending adjuvant chemotherapy for patients by giving additional chemotherapy can lengthen the amount of time before their cancer comes back. The additional chemotherapy is called capecitabine. - Capecitabine is an oral drug (taken by mouth). It is approved by the US Food and Drug Administration (FDA) for adjuvant treatment of adults with pancreatic cancer and also for the treatment of other types of cancer